-
POPULATION HEALTH IMPACTS ASSOCIATED WITH NEW INDICATIONS: A CASE STUDY OF SGLT2-INHIBITORS
Mar 18, 2026, 21:38 PM -
US MEDICINE PRICING POLICY CHANGES: IMPACT ON THE FULL BIOPHARMACEUTICAL INVESTMENT ECOSYSTEM
Mar 18, 2026, 21:38 PM -
CHOOSING PUBLIC LLMS AND AI AGENTS FOR PATIENT OUTCOMES RESEARCH: PRACTICAL PROS/CONS AND GOVERNANCE IMPLICATIONS
Mar 18, 2026, 21:38 PM -
EFFECT OF CHINESE HERBAL MEDICINE COMBINED WITH CONVENTIONAL ANTI-OSTEOPOROTIC MEDICATION ON FRACTURE RISK IN OLDER ADULTS WITH OSTEOPOROSIS: A RETROSPECTIVE COHORT STUDY
Mar 18, 2026, 21:38 PM -
COMPARATIVE EFFECTIVENESS OF SGLT2I, GLP-1, AND METFORMIN ON CARDIOVASCULAR OUTCOMES IN ADULTS WITH SEVERE MENTAL ILLNESS
Mar 18, 2026, 21:38 PM -
ETHICAL AI DEPLOYMENT IN HEOR
Mar 18, 2026, 21:38 PM -
BREAKTHROUGH THERAPY (BT) AND FAST TRACK (FT) DESIGNATIONS IN NEW DRUG APPLICATIONS AND BIOLOGIC LICENSE APPLICATIONS (NDAS/BLAS) TO FDA’S CENTER FOR DRUG EVALUATION AND RESEARCH (CDER), 2013-2025
Mar 18, 2026, 21:38 PM -
THE COST-EFFECTIVENESS ANALYSIS OF INATICABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS IN CHINA
Mar 18, 2026, 21:38 PM -
ASSESSING THE IMPACT OF MISSINGNESS IN TREATMENT EFFECT MODIFIERS ON BIAS IN ANCHORED AND UNANCHORED MAIC AND STC
Mar 18, 2026, 21:38 PM -
COMBINING DISCRETE CHOICE EXPERIMENT AND CONTINGENT VALUATION TO ESTIMATE WILLINGNESS-TO-PAY FOR LYME DISEASE VACCINE ATTRIBUTES IN THE UNITED STATES
Mar 18, 2026, 21:38 PM -
ECONOMIC BURDEN OF INCIDENT BRAIN METASTASES IN MEDICARE BENEFICIARIES WITH ALK+ METASTATIC NON-SMALL CELL LUNG CANCER
Mar 18, 2026, 21:38 PM -
USE OF REAL-TIME AI-ASSISTED LIVING SYSTEMATIC LITERATURE REVIEW (REAL-SLR) IN PROSTATE CANCER (PC) ENABLES ON-DEMAND ACCESS TO PIVOTAL CLINICAL TRIAL EVIDENCE
Mar 18, 2026, 21:38 PM -
ESTIMATING THE HEALTH OPPORTUNITY COST OF PUBLIC HEALTH EXPENDITURE IN KAZAKHSTAN: EMPIRICAL SUPPLY-SIDE COST-EFFECTIVENESS THRESHOLDS
Mar 18, 2026, 21:38 PM -
INCREASED RISK OF DIABETIC KETOACIDOSIS IN ADULTS WITH DELAYED DIAGNOSIS OF TYPE 1 DIABETES
Mar 18, 2026, 21:38 PM -
DO DATA SOURCES MATTER? COMPARING MARKET COST AND PAYER COST APPROACHES TO CALCULATING MEDICAL SPENDING MEASURES IN REAL-WORLD DATA
Mar 18, 2026, 21:38 PM -
PROBABILISTIC LINKING OF CLAIMS AND ELECTRONIC HEALTH RECORD (EHR) ENCOUNTERS USING THE FELLEGI-SUNTER STATISTICAL FRAMEWORK
Mar 18, 2026, 21:38 PM -
QUANTIFYING THE OPPORTUNITY: THE ECONOMIC AND COMMERCIAL CASE FOR ALS TREATMENT INNOVATION
Mar 18, 2026, 21:38 PM -
EVALUATING THE IMPACT OF THE INFLATION REDUCTION ACT OUT-OF-POCKET CAPS ON PATIENT ASSISTANCE FUNDS EFFICIENCY AND COVERAGE EXPANSION
Mar 18, 2026, 21:38 PM -
HEALTHCARE RESOURCE UTILIZATION AND COSTS OF DIABETES MELLITUS: A RETROSPECTIVE REAL-WORLD COST-OF-ILLNESS ANALYSIS IN BRAZIL
Mar 18, 2026, 21:38 PM -
MACHINE LEARNING EVALUATION OF RACIAL AND ETHNIC INCLUSION UNDER ALTERNATIVE COST-BASED APPROACHES TO MEDICARE MEDICATION THERAPY MANAGEMENT ELIGIBILITY
Mar 18, 2026, 21:38 PM
